Modern Healthcare writes of an Institute for Clinical and Economic Review (ICER) project that will compare the cost and benefit of costly drugs. ICER will begin releasing reports that will compare clinical effectiveness of drugs, compare prices and their potential impact on the U.S. healthcare system and economy. The agency will then set a value-based benchmark for pricing. The ICER project is funded by a $5.2 million grant from the Laura and John Arnold Foundation, a private foundation that encourages evidence-based and multidisciplinary approaches to address challenges in various sectors, including education, policy and healthcare. The reports will reference how prices are directly linked to the drugs’ ability to improve the health of patients.
Project Announced to Compare Cost, Benefit of Costly Drugs
More from United StatesMore posts in United States »
- AHRQ Stats: Most and Least Likely Groups To Have Health Insurance
- Money/The Leapfrog Group Best Hospitals for Pediatrics
- Study Finds Non Profile and Government Hospitals Have Higher Commercially Negotiated Prices for Brain MRI Than For-Profit Hospitals
- Study Found Pregnancy-Related Deaths Spiked for Second Consecutive Year During COVID-19
- Rand/MedStar Health Research Highlights Ongoing Challenges Black People Face in Receiving Quality Health Care